Recordati S.p.A. - Recordati: business objectives confirmed. Solid growth expected.

Press Releases

Recordati: business objectives confirmed. Solid growth expected.

Milan, 17 December 2001

Recordati meets with the financial community and specialized media at the Milan Stock Exchange to comment on the main events regarding the group during the last months and present its development prospects.

Recordati expects consolidated sales of € 430 million in 2001 and over € 467 million in 2002 - substantially confirming its announced targets - while profitability should improve. In fact, operating income is forecast to exceed € 60 million in 2001 and to exceed € 66 million in 2002. These estimates do not include the effect of the approval by the FDA of Zanidip® (lercanidipine), Recordati's proprietary calcium channel blocker. The NDA was filed on 1 October 2001. Should the approval be granted, operating income for 2002 could increase by around 15%.

The slides presented during the meeting can be viewed on Recordati's website www.recordati.com under the section Investor Relations.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Portugal, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2001 Print Page Bookmark Page
Shareholder information Recordati at a glance Key Financial Data Recordati Share Press Releases 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Calendar Analyst Coverage Contacts	Press Releases Recordati: business objectives confirmed. Solid growth expected. Milan, 17 December 2001 Recordati meets with the financial community and specialized media at the Milan Stock Exchange to comment on the main events regarding the group during the last months and present its development prospects. Recordati expects consolidated sales of € 430 million in 2001 and over € 467 million in 2002 - substantially confirming its announced targets - while profitability should improve. In fact, operating income is forecast to exceed € 60 million in 2001 and to exceed € 66 million in 2002. These estimates do not include the effect of the approval by the FDA of Zanidip® (lercanidipine), Recordati's proprietary calcium channel blocker. The NDA was filed on 1 October 2001. Should the approval be granted, operating income for 2002 could increase by around 15%. The slides presented during the meeting can be viewed on Recordati's website www.recordati.com under the section Investor Relations. Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Portugal, Spain, Switzerland and the United States.